CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
MWN-AI** Summary
CONMED Corporation (NYSE: CNMD) reported its financial results for the fourth quarter and full year ended December 31, 2025, showcasing growth amidst operational challenges. In Q4 2025, the company recorded sales of $373.2 million, marking a 7.9% increase year-over-year, with notable contributions from a 17.0% rise in international revenue compared to a modest 1.4% growth domestically. However, diluted net earnings per share (EPS) fell to $0.54 from $1.08 the previous year, reflecting a challenging environment. On a positive note, adjusted diluted EPS improved to $1.43, up from $1.34 in Q4 2024, indicating effective management of core operations.
For the full year 2025, CONMED reported sales of $1,374.7 million, a 5.2% increase year-over-year. Both domestic and international revenues displayed growth, with domestic up by 3.5% and international by 7.4%. Despite this revenue growth, diluted EPS decreased to $1.51 from $4.25 in 2024, while adjusted diluted EPS increased to $4.59, compared to $4.17 the previous year.
President and CEO Patrick J. Beyer expressed confidence in CONMED’s strategic focus for 2026, targeting revenue between $1.345 billion and $1.375 billion, which suggests an organic growth rate of approximately 4.5% to 6%. The company aims for adjusted diluted EPS in the range of $4.30 to $4.45, which accounts for some currency tailwinds.
CONMED’s management emphasizes operational optimization and key growth initiatives in minimally invasive surgery and other sectors as drivers for long-term success. A conference call to elaborate on these results will be held later today, fostering engagement with investors.
MWN-AI** Analysis
CONMED Corporation (NYSE: CNMD) recently released its financial results for the fourth quarter and full-year 2025, showcasing a mix of growth in sales and challenges reflected in its earnings per share (EPS). The company reported fourth-quarter sales of $373.2 million, a notable year-over-year increase of 7.9%, driven primarily by a significant surge of 17% in international revenue. However, domestic growth remained subdued at 1.4%.
While the company's adjusted diluted EPS increased to $1.43 from $1.34 in Q4 2024, diluted net earnings plummeted to $0.54 compared to $1.08 in the same quarter last year. This discrepancy highlights an underlying deterioration in profitability driven by increased operating costs and strategic shifts, including operational optimization efforts.
For investors, the outlook appears cautiously optimistic with the 2026 revenue forecast suggesting a modest growth of 4.5% to 6% in constant currency. This steady growth trajectory is expected despite the challenges facing the operation segment, particularly in orthopedics and general surgery which are pivotal for CONMED's strategy. The management also reiterated its focus on driving consistent growth through key initiatives in minimally invasive surgery and smoke evacuation technologies.
From a market perspective, the current valuation should be considered against the backdrop of these mixed results. Although the company’s fundamentals indicate long-term potential, the significant decrease in GAAP EPS signals financial volatility. Investors should closely monitor the upcoming earnings and operational performance while considering the potential benefits of operational efficiencies and sales momentum.
Overall, while CONMED presents attractive long-term growth potential, the near-term operational challenges might allow for a more opportunistic entry point as investors await clearer signs of stabilization in profitability. As always, diversification and vigilance in monitoring market conditions are essential.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025.
Fourth Quarter 2025 Highlights
- Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency.
- Domestic revenue increased 1.4% year-over-year.
- International revenue increased 17.0% year-over-year as reported and 15.4% in constant currency.
- Diluted net earnings per share (GAAP) were $0.54, compared to diluted net earnings per share (GAAP) of $1.08 in the fourth quarter of 2024.
- Adjusted diluted net earnings per share (1) were $1.43, compared to adjusted diluted net earnings per share of $1.34 in the fourth quarter of 2024.
Full-Year 2025 Highlights
- Sales of $1,374.7 million increased 5.2% year-over-year as reported and 5.1% in constant currency.
- Domestic revenue increased 3.5% year-over-year.
- International revenue increased 7.4% year-over-year as reported and 7.1% in constant currency.
- Diluted net earnings per share (GAAP) were $1.51, compared to diluted net earnings per share (GAAP) of $4.25 in 2024.
- Adjusted diluted net earnings per share (1) were $4.59, compared to adjusted diluted net earnings per share of $4.17 in 2024.
“Our fourth quarter results reflect steady execution across the business as well as progress on our operational initiatives,” said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. “As we begin 2026 with a sharpened strategic focus, we remain disciplined in our operating approach and confident in the long?term potential of our key growth drivers in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.”
2026 Outlook
The Company expects full-year 2026 reported revenue between $1.345 billion and $1.375 billion. This represents year over year organic constant currency growth of approximately 4.5% to 6% over 2025 revenue when excluding sales of gastroenterology products from both years, and approximately 0 to 50 basis points of currency tailwind.
The Company expects full-year 2026 adjusted diluted net earnings per share (2) in the range of $4.30 to $4.45. This includes a currency tailwind of approximately $0.10.
Supplemental Financial Disclosures
(1) A reconciliation of reported diluted net earnings per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears below.
(2) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below.
Conference Call
The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its fourth quarter and full-year 2025 results.
To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.
This conference call will also be webcast and can be accessed from the “Investors” section of CONMED's website at www.conmed.com . The webcast replay of the call will be available at the same site approximately one hour after the end of the call.
Consolidated Condensed Statements of Income | ||||||||||||||||
(in thousands except per share amounts, unaudited) | ||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||
December 31, | December 31, | |||||||||||||||
2025 | 2024 | 2025 | 2024 | |||||||||||||
Net sales | $ | 373,198 | $ | 345,944 | $ | 1,374,724 | $ | 1,307,015 | ||||||||
Cost of sales | 154,912 | 147,600 | 624,249 | 573,983 | ||||||||||||
Gross profit | 218,286 | 198,344 | 750,475 | 733,032 | ||||||||||||
% of sales | 58.5 | % | 57.3 | % | 54.6 | % | 56.1 | % | ||||||||
Selling & administrative expense | 166,764 | 132,669 | 591,969 | 478,280 | ||||||||||||
Research & development expense | 14,899 | 13,176 | 55,884 | 54,426 | ||||||||||||
Income from operations | 36,623 | 52,499 | 102,622 | 200,326 | ||||||||||||
% of sales | 9.8 | % | 15.2 | % | 7.5 | % | 15.3 | % | ||||||||
Interest expense | 7,370 | 8,857 | 31,087 | 37,297 | ||||||||||||
Other expense | - | - | 418 | - | ||||||||||||
Income before income taxes | 29,253 | 43,642 | 71,117 | 163,029 | ||||||||||||
Provision for income taxes | 12,514 | 9,888 | 24,062 | 30,606 | ||||||||||||
Net income | $ | 16,739 | $ | 33,754 | $ | 47,055 | $ | 132,423 | ||||||||
Basic EPS | $ | 0.54 | $ | 1.09 | $ | 1.52 | $ | 4.29 | ||||||||
Diluted EPS | 0.54 | 1.08 | 1.51 | 4.25 | ||||||||||||
Basic shares | 30,968 | 30,923 | 31,036 | 30,846 | ||||||||||||
Diluted shares | 31,030 | 31,146 | 31,149 | 31,150 |
Sales Summary | |||||||||||||||||||||
(in millions, unaudited) | |||||||||||||||||||||
Three Months Ended December 31, | |||||||||||||||||||||
% Change | |||||||||||||||||||||
Domestic | International | ||||||||||||||||||||
2025 | 2024 | As | Impact of | Constant | As | As | Impact of | Constant | |||||||||||||
Orthopedic Surgery | $ | 157.4 | $ | 139.0 | 13.2 | % | -1.1 | % | 12.1 | % | 6.6 | % | 17.5 | % | -1.8 | % | 15.7 | % | |||
General Surgery | 215.8 | 206.9 | 4.3 | % | -0.5 | % | 3.8 | % | -0.4 | % | 16.3 | % | -1.5 | % | 14.8 | % | |||||
$ | 373.2 | $ | 345.9 | 7.9 | % | -0.8 | % | 7.1 | % | 1.4 | % | 17.0 | % | -1.6 | % | 15.4 | % | ||||
Single-use Products | $ | 320.6 | $ | 297.3 | 7.8 | % | -0.7 | % | 7.1 | % | 1.5 | % | 17.6 | % | -1.7 | % | 15.9 | % | |||
Capital Products | 52.6 | 48.6 | 8.2 | % | -0.9 | % | 7.3 | % | 1.4 | % | 14.4 | % | -1.6 | % | 12.8 | % | |||||
$ | 373.2 | $ | 345.9 | 7.9 | % | -0.8 | % | 7.1 | % | 1.4 | % | 17.0 | % | -1.6 | % | 15.4 | % | ||||
Domestic | $ | 206.2 | $ | 203.3 | 1.4 | % | 0.0 | % | 1.4 | % | |||||||||||
International | 167.0 | 142.6 | 17.0 | % | -1.6 | % | 15.4 | % | |||||||||||||
$ | 373.2 | $ | 345.9 | 7.9 | % | -0.8 | % | 7.1 | % | ||||||||||||
Year Ended December 31, | |||||||||||||||||||||
% Change | |||||||||||||||||||||
Domestic | International | ||||||||||||||||||||
2025 | 2024 | As | Impact of | Constant | As | As | Impact of | Constant | |||||||||||||
Orthopedic Surgery | $ | 574.6 | $ | 544.0 | 5.6 | % | -0.1 | % | 5.5 | % | 2.3 | % | 7.8 | % | -0.2 | % | 7.6 | % | |||
General Surgery | 800.1 | 763.0 | 4.9 | % | -0.2 | % | 4.7 | % | 4.0 | % | 6.9 | % | -0.5 | % | 6.4 | % | |||||
$ | 1,374.7 | $ | 1,307.0 | 5.2 | % | -0.1 | % | 5.1 | % | 3.5 | % | 7.4 | % | -0.3 | % | 7.1 | % | ||||
Single-use Products | $ | 1,183.8 | $ | 1,112.1 | 6.4 | % | -0.1 | % | 6.3 | % | 4.0 | % | 9.9 | % | -0.3 | % | 9.6 | % | |||
Capital Products | 190.9 | 194.9 | -2.1 | % | 0.0 | % | -2.1 | % | -0.3 | % | -3.6 | % | -0.2 | % | -3.8 | % | |||||
$ | 1,374.7 | $ | 1,307.0 | 5.2 | % | -0.1 | % | 5.1 | % | 3.5 | % | 7.4 | % | -0.3 | % | 7.1 | % | ||||
Domestic | $ | 774.6 | $ | 748.2 | 3.5 | % | 0.0 | % | 3.5 | % | |||||||||||
International | 600.1 | 558.8 | 7.4 | % | -0.3 | % | 7.1 | % | |||||||||||||
$ | 1,374.7 | $ | 1,307.0 | 5.2 | % | -0.1 | % | 5.1 | % | ||||||||||||
Reconciliation of Reported Net Income to Adjusted Net Income | |||||||||||||||||||||||||||
(in thousands, except per share amounts, unaudited) | |||||||||||||||||||||||||||
Three Months Ended December 31, 2025 | |||||||||||||||||||||||||||
Gross Profit | Selling & | Research & | Operating | Interest | Other | Tax Expense | Effective Tax | Net Income | Diluted EPS | ||||||||||||||||||
As reported | $ | 218,286 | $ | 166,764 | $ | 14,899 | $ | 36,623 | $ | 7,370 | $ | - | $ | 12,514 | 42.8 | % | $ | 16,739 | $ | 0.54 | |||||||
% of sales | 58.5 | % | 44.7 | % | 4.0 | % | 9.8 | % | |||||||||||||||||||
Contingent consideration fair value adjustments (1) | - | (19,446 | ) | - | 19,446 | - | - | 278 | 19,168 | ||||||||||||||||||
Product rationalization costs (2) | 2,596 | (2,234 | ) | - | 4,830 | - | - | 69 | 4,761 | ||||||||||||||||||
Operational optimization consulting fees (3) | 188 | (4,469 | ) | - | 4,657 | - | - | 67 | 4,590 | ||||||||||||||||||
EU medical device regulations (4) | - | - | (785 | ) | 785 | - | - | 11 | 774 | ||||||||||||||||||
Legal matters (5) | - | (60 | ) | - | 60 | - | - | 1 | 59 | ||||||||||||||||||
Termination of distribution agreement (6) | (9,866 | ) | - | - | (9,866 | ) | - | - | (141 | ) | (9,725 | ) | |||||||||||||||
$ | 211,204 | $ | 140,555 | $ | 14,114 | $ | 56,535 | $ | 7,370 | $ | - | $ | 12,799 | $ | 36,366 | ||||||||||||
Adjusted gross profit % | 56.6 | % | |||||||||||||||||||||||||
Amortization (7) | $ | 1,500 | (7,591 | ) | - | 9,091 | (1,539 | ) | - | 2,563 | 8,067 | ||||||||||||||||
As adjusted | $ | 132,964 | $ | 14,114 | $ | 65,626 | $ | 5,831 | $ | - | $ | 15,362 | 25.7 | % | $ | 44,433 | $ | 1.43 | |||||||||
% of sales | 35.6 | % | 3.8 | % | 17.6 | % | |||||||||||||||||||||
Three Months Ended December 31, 2024 | |||||||||||||||||||||||||||
Gross Profit | Selling & | Research & | Operating | Interest | Other | Tax Expense | Effective Tax | Net Income | Diluted EPS | ||||||||||||||||||
As reported | $ | 198,344 | $ | 132,669 | $ | 13,176 | $ | 52,499 | $ | 8,857 | $ | - | $ | 9,888 | 22.7 | % | $ | 33,754 | $ | 1.08 | |||||||
% of sales | 57.3 | % | 38.3 | % | 3.8 | % | 15.2 | % | |||||||||||||||||||
Contingent consideration fair value adjustments (1) | - | (1,219 | ) | - | 1,219 | - | - | 1,058 | 161 | ||||||||||||||||||
Hurricane impact (8) | 955 | - | - | 955 | - | - | 829 | 126 | |||||||||||||||||||
Lease impairment (9) | - | (606 | ) | - | 606 | - | - | 526 | 80 | ||||||||||||||||||
Legal matters (5) | - | (531 | ) | - | 531 | - | - | 461 | 70 | ||||||||||||||||||
$ | 199,299 | $ | 130,313 | $ | 13,176 | $ | 55,810 | $ | 8,857 | $ | - | $ | 12,762 | $ | 34,191 | ||||||||||||
Adjusted gross profit % | 57.6 | % | |||||||||||||||||||||||||
Amortization (7) | $ | 1,500 | (7,162 | ) | - | 8,662 | (1,443 | ) | - | 2,456 | 7,649 | ||||||||||||||||
As adjusted | $ | 123,151 | $ | 13,176 | $ | 64,472 | $ | 7,414 | $ | - | $ | 15,218 | 26.7 | % | $ | 41,840 | $ | 1.34 | |||||||||
% of sales | 35.6 | % | 3.8 | % | 18.6 | % | |||||||||||||||||||||
(1) In 2025 and 2024, the Company recorded expense related to the fair value adjustments of contingent consideration. |
(2) In 2025, the Company wrote off inventory, equipment, tooling and patents to cost of goods sold related to the cancellation of planned new product lines and discontinuation of certain catalog numbers as a result of our operational optimization consultation and internal review. In addition, we wrote off the developed technology intangible asset to selling and administrative expense. |
(3) In 2025, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales. In addition, we incurred consulting fees and other charges related to operational optimization which are included in selling & administrative expense. |
(4) In 2025, the Company incurred costs to comply with the European Union's Medical Device Regulations (MDR). |
(5) In 2025 and 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to design surgeons. |
(6) In 2025, the Company incurred income related to the early termination of an agreement granting the Company exclusive distribution rights. |
(7) Includes amortization of intangible assets and deferred financing fees. |
(8) In 2024, the Company incurred costs due to the impact of Hurricane Milton on our Largo, FL facility. These costs were mainly comprised of emergency pay to employees and plant underutilization due to abnormally low production. |
(9) In 2024, the Company recorded lease impairment expense related to a storage facility no longer utilized. |
Reconciliation of Reported Net Income to Adjusted Net Income | ||||||||||||||||||||||||||||
(in thousands, except per share amounts, unaudited) | ||||||||||||||||||||||||||||
Year Ended December 31, 2025 | ||||||||||||||||||||||||||||
Gross Profit | Selling & | Research & | Operating | Interest | Other | Tax Expense | Effective | Net Income | Diluted EPS | |||||||||||||||||||
As reported | $ | 750,475 | $ | 591,969 | $ | 55,884 | $ | 102,622 | $ | 31,087 | $ | 418 | $ | 24,062 | 33.8 | % | $ | 47,055 | $ | 1.51 | ||||||||
% of sales | 54.6 | % | 43.1 | % | 4.1 | % | 7.5 | % | ||||||||||||||||||||
Operational optimization costs (1) | 12,450 | (12,926 | ) | - | 25,376 | - | - | 4,112 | 21,264 | |||||||||||||||||||
Product rationalization costs (2) | 22,249 | (2,234 | ) | - | 24,483 | - | - | 4,940 | 19,543 | |||||||||||||||||||
Contingent consideration fair value adjustments (3) | - | (22,951 | ) | - | 22,951 | - | - | 1,324 | 21,627 | |||||||||||||||||||
Executive transition costs (4) | - | (12,165 | ) | - | 12,165 | - | - | 2,812 | 9,353 | |||||||||||||||||||
EU medical device regulations (5) | - | - | (785 | ) | 785 | - | - | 11 | 774 | |||||||||||||||||||
Debt refinancing costs (6) | - | - | - | - | - | (418 | ) | 47 | 371 | |||||||||||||||||||
Legal matters (7) | - | (2,609 | ) | - | 2,609 | - | - | 454 | 2,155 | |||||||||||||||||||
Gain on sale of product line (8) | - | 354 | - | (354 | ) | - | - | (82 | ) | (272 | ) | |||||||||||||||||
Termination of distribution agreement (9) | (9,866 | ) | - | - | (9,866 | ) | - | - | (141 | ) | (9,725 | ) | ||||||||||||||||
$ | 775,308 | $ | 539,438 | $ | 55,099 | $ | 180,771 | $ | 31,087 | $ | - | $ | 37,539 | $ | 112,145 | |||||||||||||
Adjusted gross profit % | 56.4 | % | ||||||||||||||||||||||||||
Amortization (10) | $ | 6,000 | (29,188 | ) | - | 35,188 | (5,646 | ) | - | 9,898 | 30,936 | |||||||||||||||||
As adjusted | $ | 510,250 | $ | 55,099 | $ | 215,959 | $ | 25,441 | $ | - | $ | 47,437 | 24.9 | % | $ | 143,081 | $ | 4.59 | ||||||||||
% of sales | 37.1 | % | 4.0 | % | 15.7 | % | ||||||||||||||||||||||
Year Ended December 31, 2024 | ||||||||||||||||||||||||||||
Gross Profit | Selling & | Research & | Operating | Interest | Other | Tax Expense | Effective | Net Income | Diluted EPS | |||||||||||||||||||
As reported | $ | 733,032 | $ | 478,280 | $ | 54,426 | $ | 200,326 | $ | 37,297 | $ | - | $ | 30,606 | 18.8 | % | $ | 132,423 | $ | 4.25 | ||||||||
% of sales | 56.1 | % | 36.6 | % | 4.2 | % | 15.3 | % | ||||||||||||||||||||
Legal matters (7) | - | (5,097 | ) | - | 5,097 | - | - | 806 | 4,291 | |||||||||||||||||||
Restructuring and related costs (11) | 235 | (1,539 | ) | - | 1,774 | - | - | 255 | 1,519 | |||||||||||||||||||
Product rationalization costs (2) | 1,414 | - | - | 1,414 | - | - | 203 | 1,211 | ||||||||||||||||||||
Hurricane impact (12) | 955 | - | - | 955 | - | - | 829 | 126 | ||||||||||||||||||||
Lease impairment (13) | - | (606 | ) | - | 606 | - | - | 526 | 80 | |||||||||||||||||||
Termination of distributor agreement (14) | - | 970 | - | (970 | ) | - | - | (139 | ) | (831 | ) | |||||||||||||||||
Contingent consideration fair value adjustments (3) | - | 41,048 | - | (41,048 | ) | - | - | (1,591 | ) | (39,457 | ) | |||||||||||||||||
$ | 735,636 | $ | 513,056 | $ | 54,426 | $ | 168,154 | $ | 37,297 | $ | - | $ | 31,495 | $ | 99,362 | |||||||||||||
Adjusted gross profit % | 56.3 | % | ||||||||||||||||||||||||||
Amortization (10) | $ | 6,000 | (28,629 | ) | - | 34,629 | (5,700 | ) | - | 9,775 | 30,554 | |||||||||||||||||
As adjusted | $ | 484,427 | $ | 54,426 | $ | 202,783 | $ | 31,597 | $ | - | $ | 41,270 | 24.1 | % | $ | 129,916 | $ | 4.17 | ||||||||||
% of sales | 37.1 | % | 4.2 | % | 15.5 | % |
(1) In 2025, the Company incurred costs related to the engagement of a consulting firm to evaluate and propose improvements to our manufacturing operations which are included in cost of sales. In addition, we incurred consulting fees and other charges related to operational optimization which are included in selling & administrative expense. |
(2) In 2025, the Company wrote off inventory, equipment, tooling and patents to cost of goods sold related to the cancellation of planned new product lines and discontinuation of certain catalog numbers as a result of our operational optimization consultation and internal review. In addition, we wrote off the developed technology intangible asset to selling and administrative expense. In 2024, the Company wrote off inventory, tooling and equipment related to the cancellation of a planned new product line. |
(3) In 2025 and 2024, the Company recorded income/(expense) related to the fair value adjustments of contingent consideration. |
(4) In 2025, the Company incurred cash and stock-based compensation costs related to advisory services provided by our former Chief Executive Officer. |
(5) In 2025, the Company incurred costs to comply with the European Union's Medical Device Regulations (MDR). |
(6) In 2025, the Company incurred costs related to a loss on early extinguishment and third-party fees associated with the eighth amended and restated senior credit agreement. |
(7) In 2025 and 2024, the Company incurred costs for third party services pertaining to potential issues with certain royalty payments to design surgeons. |
(8) In 2025, the Company recognized a gain on the sale of a product line. |
(9) In 2025, the Company incurred income related to the early termination of an agreement granting the Company exclusive distribution rights. |
(10) Includes amortization of intangible assets and deferred financing fees. |
(11) In 2024, the Company incurred severance costs related to the elimination of certain positions. |
(12) In 2024, the Company incurred costs due to the impact of Hurricane Milton on our Largo, FL facility. These costs were mainly comprised of emergency pay to employees and plant underutilization due to abnormally low production. |
(13) In 2024, the Company recorded lease impairment expense related to a storage facility no longer utilized. |
(14) In 2024, the Company recorded an accrual adjustment related to the previous termination of a distributor agreement. |
Reconciliation of Reported Net Income to EBITDA & Adjusted EBITDA | |||||||||||||||
(in thousands, unaudited) | |||||||||||||||
Three Months Ended | Year Ended | ||||||||||||||
December 31, | December 31, | ||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
Net income | $ | 16,739 | $ | 33,754 | $ | 47,055 | $ | 132,423 | |||||||
Provision for income taxes | 12,514 | 9,888 | 24,062 | 30,606 | |||||||||||
Interest expense | 7,370 | 8,857 | 31,087 | 37,297 | |||||||||||
Depreciation | 4,066 | 4,199 | 17,143 | 16,605 | |||||||||||
Amortization | 14,784 | 13,807 | 57,138 | 55,252 | |||||||||||
EBITDA | $ | 55,473 | $ | 70,505 | $ | 176,485 | $ | 272,183 | |||||||
Stock-based compensation | 4,972 | 6,222 | 20,841 | 25,558 | |||||||||||
Contingent consideration fair value adjustments | 19,446 | 1,219 | 22,951 | (41,048 | ) | ||||||||||
Product rationalization costs | 4,830 | - | 24,483 | 1,414 | |||||||||||
Operational optimization costs | 4,657 | - | 25,376 | - | |||||||||||
EU medical device regulations | 785 | - | 785 | - | |||||||||||
Legal matters | 60 | 531 | 2,609 | 5,097 | |||||||||||
Restructuring and related costs | - | - | - | 1,774 | |||||||||||
Executive transition costs | - | - | 12,165 | - | |||||||||||
Debt refinancing costs | - | - | 418 | - | |||||||||||
Gain on sale of product line | - | - | (354 | ) | - | ||||||||||
Hurricane impact | - | 955 | - | 955 | |||||||||||
Lease impairment | - | 606 | - | 606 | |||||||||||
Termination of distribution agreement | (9,866 | ) | - | (9,866 | ) | - | |||||||||
Termination of distributor agreement | - | - | - | (970 | ) | ||||||||||
Adjusted EBITDA | $ | 80,357 | $ | 80,038 | $ | 275,893 | $ | 265,569 | |||||||
EBITDA Margin | |||||||||||||||
EBITDA | 14.9 | % | 20.4 | % | 12.8 | % | 20.8 | % | |||||||
Adjusted EBITDA | 21.5 | % | 23.1 | % | 20.1 | % | 20.3 | % |
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com .
Forward-Looking Statements
This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures
The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted research and development expense; adjusted operating income; adjusted interest expense; adjusted other expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures.
Net sales on a constant currency basis is a non-GAAP measure. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends.
Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, research and development expense, operating income, interest expense, other expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure.
We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260128818404/en/
CONMED Corporation
Pat Beyer
Chief Executive Officer
PatBeyer@conmed.com
FAQ**
Given the reported 7.9% increase in sales for the fourth quarter 2025 for Conmed Corp. - Ordinary Shares CNMD, what specific strategies did the company implement to achieve this growth, particularly in their international markets?
With diluted net earnings per share (GAAP) decreasing to $0.54 for Q4 20compared to $1.08 in Q4 20at Conmed Corp. - Ordinary Shares CNMD, what factors contributed to this decline in profitability despite the revenue growth?
As Conmed Corp. - Ordinary Shares CNMD expects a revenue projection of $1.345 to $1.375 billion for 2026, how does the company plan to navigate potential challenges that could impact growth, such as global economic conditions or supply chain issues?
How does Conmed Corp. - Ordinary Shares CNMD intend to leverage its advancements in minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair to sustain long-term growth amid the reported fluctuations in quarterly earnings and operational expenses?
**MWN-AI FAQ is based on asking OpenAI questions about Conmed Corp. - Ordinary Shares (NYSE: CNMD).
NASDAQ: CNMD
CNMD Trading
-5.9% G/L:
$39.655 Last:
141,230 Volume:
$40.96 Open:
